News Sentiment

MGNX sentiment intelligence

MacroGenics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.33 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-8.1% over one week, +9.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

[144] MACROGENICS INC SEC Filing

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -8.1% Price reacting lower
Trend fit Trend active 9.3% over four weeks
Fair value -8.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 10
Stock Titan 6
Investing.com 4
simplywall.st 4
Seeking Alpha 3
www.marketscreener.com 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 15
Regulatory and legal 7
Deals and strategy 6
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Investing.com Direct company coverage

MacroGenics stock rises on $24.5M Sanofi milestone payment

MacroGenics Inc. (NASDAQ:MGNX) saw its shares increase after-hours due to a $24.5 million milestone payment from Sanofi. This payment followed FDA accelerated approval for TZIELD (teplizumab-mzwv) which expands its use for delaying the decline in insulin production in children wi

Tone
Positive 70/100
Event
Regulatory and legal
Published
22 Jun 2026 21:10
Source
Investing.com